NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Updated: Feb 10
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-cell Marginal Zone
Lymphoma, Non-Hodgkin
Multiple Myeloma
B-cell Lymphoma
Waldenstrom Macroglobulinemia
Lymphoma, Mantle-Cell
Sponsor
Eli Lilly and Company
Collaborator
Loxo Oncology, Inc
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT05024045
Official Title: A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
First Posted : August 27, 2021
Click here for details on ClinicalTrials.gov
Drug: LOXO-338
Bcl-2 inhibitor LOXO-338
Drug: Pirtobrutinib
BTK inhibitor LOXO-305
Bcl-2 inhibitor LOXO-338
BTK inhibitor LOXO-305
Locations
United States, Florida
United States, Indiana
United States, Kansas
United States, Minnesota
United States, New York
United States, Washington
United States, Wisconsin
Europe
France
Poland